

A

Weeks of ART	Sample		# Sequences (Unique)	APD (<i>pro</i> -RT)	Drug Resistance Mutations		Population Shifts
	Source	Type			<i>pro</i> -RT	(%)	
0	Plasma	RNA	34	0.8	NONE	NONE	Reference
11	PBMC	DNA	19	0.9	NONE	NONE	No
		RNA	20	0.7	NONE	NONE	No
24	PBMC	DNA	32	0.7	NONE	NONE	Yes
		RNA	17	1.1	NONE	NONE	No
46	PBMC	DNA	27	0.8	NONE	NONE	Yes
		RNA	13	0.8	M184I	E92Q	No
54	PBMC	DNA	27	0.9	NONE	NONE	Yes
54	CSF	RNA	5	-	M184I	E92Q	Insufficient sequences for analyses
104	PBMC	DNA	24	0.8	M184I	E92Q	Yes
117	Lymph node	DNA	61	0.8	M184I, M184V	E92Q	Yes
133	Rectum	DNA	22	0.6	NONE	NONE	Yes
133	Sigmoid	DNA	21	0.8	NONE	NONE	Yes

B

HIV-1 PCR target	Primer name	Primer's designation	Primer sequence 5' → 3'
Protease-Reverse Transcriptase (<i>pro</i> -RT)	3500-1849+	Reverse transcription, 1 st round PCR	GATGACAGCATGTCAGGGAG
	1870+3410-	1 st round PCR	CTATTAAGTATTTTGGTGGGCATAA
	1870+3410-	2 nd Round PCR, sequencing	CACTTAGTGGTATTACTTCTGTTAGTGCTT
	2030+3410-	2 nd Round PCR, sequencing	GAGTTTGGCTGAGGCAAT
	2030+2600+	Sequencing	TGTTGGAAATGTGGAAAGGAAGGAC
	2600+2610-	Sequencing	ATGGCCAAAAGTTAAACAATGGC
	2610-3330-	Sequencing	TTCTTCTGTCAATGGCCATTGTTTAAAC
	3330-	Sequencing	TGCCCCAATTCAATTTTCCACTAA
Integrase (IN)	INREV-I	Reverse transcription, 1 st round PCR	TCTCCTGTATGCAGACCCCAATAT
	HIV+4141	1 st round PCR	TCTACCTGGCATGGGTACCA
	POLK-	2 nd Round PCR, sequencing	CCTTGACTTTGGGGATTGTAGGGAA
	POLZ	2 nd Round PCR, sequencing	AATTTTCGGGTTTATTACAG
	INREV-II	Sequencing	CCTAGTGGGATGTGTACTTCTGA
Envelope (<i>env</i>)	Random hexamers	Reverse transcription	Invitrogen™; Cat# N8080127
	envB5out	1 st round PCR	TAGAGCCCTGGAAGCATCCAGGAAG
	envB3out	1 st round PCR	TTGCTACTTGTGATTGCTCCATGT
	envB5in	2 nd Round PCR, sequencing	TTAGGCATCTCCTATGGCAGGAAGAAG
	envB3in	2 nd Round PCR, sequencing	GTCTCGAGATACTGCTCCCACCC
	For14	Sequencing	TATGGGACCAAAGCCTAAAGCCATGTG
	For16	Sequencing	TTTAATTGTGGAGGAGAATTTTCTA
	For18	Sequencing	CATATCAAATTGGCTGTGGTATAT
	Rev15	Sequencing	CTGCCATTTAACAGCAGTTGAGTTGA
	Rev16	Sequencing	ATGGGAGGGGCATACATTGCT
Rev18	Sequencing	GGTGAGTATCCCTGCCTAACTCTAT	

Supplemental Table 1. (A) Summary of drug resistance and population genetics analyses of *pro*-RT populations, and (B) nucleotide primers used to generate HIV-1 *pro*-RT, *IN* and *env*.